OncoMatch/Clinical Trials/NCT06454968

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Is NCT06454968 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Orelabrutinib, obinutuzumab, lenalidomide for marginal zone lymphoma.

Phase 2RecruitingPeking Union Medical College HospitalNCT06454968Data as of May 2026

Treatment: Orelabrutinib, obinutuzumab, lenalidomide — This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Disease stage

Required: Stage ANN ARBOR NON-CONTINUOUS STAGE II, STAGE III-IV NON-GASTRIC MALT AND NODAL MZL, LUGANO STAGE II2, LUGANO STAGE IIE, LUGANO STAGE IV

Ann Arbor non-continuous Stage II or Stage III-IV non-gastric MALT and nodal MZL; SMZL (Splenic Marginal Zone Lymphoma); Gastric MALT with Lugano Stage II2/IIE/IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify